End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.8 CNY | -6.95% | +11.47% | +36.50% |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 69 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.50% | 818M | - | ||
+9.17% | 4.08B | D+ | ||
+8.03% | 1.81B | B+ | ||
+23.43% | 1.15B | - | ||
+8.03% | 1.04B | D+ | ||
+65.59% | 714M | - | - | |
-3.86% | 697M | - | - | |
+34.34% | 597M | B- | ||
+11.13% | 464M | - | D+ | |
-6.64% | 424M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300758 Stock
- Ratings Anshan Hifichem Co., Ltd.